CVS Health Corp vs Vanguard Mega Cap Growth ETF — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Vanguard Mega Cap Growth ETF trades at $94.92 (market cap $33.70B). The key difference: CVS Health Corp is far larger — about 3.3× Vanguard Mega Cap Growth ETF's market cap, and CVS Health Corp pays a 3.02% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vanguard Mega Cap Growth ETF for 45 Days on average.
| CVS | MGK | |
|---|---|---|
Market Cap | $112.49B | $33.70B |
Volume | 8,467,392 | 1,290,406 |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $95.11 |
52-Week Low | $70.08 | $70.70 |
Typical Hold Time | 83 Days | 45 Days |
Enterprise Value | $174.83B | — |
Dividend Yield | 3.02% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
MGK trades at $94.92, down 0.2% on the day, with a bullish technical signal from moving averages but bearish momentum from oscillators. The ETF focuses on large-cap US growth stocks with heavy technology concentration, offering low 0.05% expense ratio exposure to companies like Nvidia, Apple, and Microsoft. Recent articles highlight its strong five-year performance and appeal for long-term growth investors seeking mega-cap stability.
MGK presents a compelling growth ETF option with concentrated mega-cap exposure, though its tech-heavy composition increases sector-specific risk. The fund's low costs and historical outperformance make it suitable for investors with higher risk tolerance, while current technical indicators suggest potential near-term consolidation after recent gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →